human ll 37 elisa kit Search Results


95
Hycult Biotech elisa kit
Elisa Kit, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/elisa kit/product/Hycult Biotech
Average 95 stars, based on 1 article reviews
elisa kit - by Bioz Stars, 2026-03
95/100 stars
  Buy from Supplier

94
Bio-Techne corporation ll37
Ll37, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ll37/product/Bio-Techne corporation
Average 94 stars, based on 1 article reviews
ll37 - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier

92
Cusabio human il 37 elisa reagent kits
Human Il 37 Elisa Reagent Kits, supplied by Cusabio, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human il 37 elisa reagent kits/product/Cusabio
Average 92 stars, based on 1 article reviews
human il 37 elisa reagent kits - by Bioz Stars, 2026-03
92/100 stars
  Buy from Supplier

93
Cusabio csb e14948h
Csb E14948h, supplied by Cusabio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/csb e14948h/product/Cusabio
Average 93 stars, based on 1 article reviews
csb e14948h - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

91
R&D Systems human il 37 elisa kit
Human Il 37 Elisa Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human il 37 elisa kit/product/R&D Systems
Average 91 stars, based on 1 article reviews
human il 37 elisa kit - by Bioz Stars, 2026-03
91/100 stars
  Buy from Supplier

90
Adipogen recombinant human il 37
Interleukin <t>(IL)–37</t> reduces myocardial infarct size and improves left ventricular function following myocardial infarction (MI). A, Survival analysis in PBS ‐treated and IL ‐37–treated mice after MI . B, Infarct size determined by 2, 3, 5‐triphenyltetrazolium chloride staining of sections on day 1 post‐ MI ( PBS ‐treated group n=6 and IL ‐37–treated group n=8). C, Representative M‐mode echocardiography images of the left ventricle on day 28 post‐ MI . Left ventricular end‐diastolic dimension (LVEDD), left ventricular end‐systolic dimension (LVESD), ejection fraction (EF%), and fractional shortening (FS%) on day 7 (D) and day 28 (E) post‐ MI (Sham n=6, PBS ‐treated group n=6, and IL ‐37‐treated group n=8). * P <0.05 and ** P <0.01.
Recombinant Human Il 37, supplied by Adipogen, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant human il 37/product/Adipogen
Average 90 stars, based on 1 article reviews
recombinant human il 37 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Elabscience Biotechnology elisa kits for il-37 assay
Interleukin <t>(IL)–37</t> reduces myocardial infarct size and improves left ventricular function following myocardial infarction (MI). A, Survival analysis in PBS ‐treated and IL ‐37–treated mice after MI . B, Infarct size determined by 2, 3, 5‐triphenyltetrazolium chloride staining of sections on day 1 post‐ MI ( PBS ‐treated group n=6 and IL ‐37–treated group n=8). C, Representative M‐mode echocardiography images of the left ventricle on day 28 post‐ MI . Left ventricular end‐diastolic dimension (LVEDD), left ventricular end‐systolic dimension (LVESD), ejection fraction (EF%), and fractional shortening (FS%) on day 7 (D) and day 28 (E) post‐ MI (Sham n=6, PBS ‐treated group n=6, and IL ‐37‐treated group n=8). * P <0.05 and ** P <0.01.
Elisa Kits For Il 37 Assay, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/elisa kits for il-37 assay/product/Elabscience Biotechnology
Average 90 stars, based on 1 article reviews
elisa kits for il-37 assay - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Abbexa Ltd human antibacterial protein ll-37 elisa kit
Interleukin <t>(IL)–37</t> reduces myocardial infarct size and improves left ventricular function following myocardial infarction (MI). A, Survival analysis in PBS ‐treated and IL ‐37–treated mice after MI . B, Infarct size determined by 2, 3, 5‐triphenyltetrazolium chloride staining of sections on day 1 post‐ MI ( PBS ‐treated group n=6 and IL ‐37–treated group n=8). C, Representative M‐mode echocardiography images of the left ventricle on day 28 post‐ MI . Left ventricular end‐diastolic dimension (LVEDD), left ventricular end‐systolic dimension (LVESD), ejection fraction (EF%), and fractional shortening (FS%) on day 7 (D) and day 28 (E) post‐ MI (Sham n=6, PBS ‐treated group n=6, and IL ‐37‐treated group n=8). * P <0.05 and ** P <0.01.
Human Antibacterial Protein Ll 37 Elisa Kit, supplied by Abbexa Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human antibacterial protein ll-37 elisa kit/product/Abbexa Ltd
Average 90 stars, based on 1 article reviews
human antibacterial protein ll-37 elisa kit - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Hangzhou Eastbiopharm Co human il-37 elisa kit
Interleukin <t>(IL)–37</t> reduces myocardial infarct size and improves left ventricular function following myocardial infarction (MI). A, Survival analysis in PBS ‐treated and IL ‐37–treated mice after MI . B, Infarct size determined by 2, 3, 5‐triphenyltetrazolium chloride staining of sections on day 1 post‐ MI ( PBS ‐treated group n=6 and IL ‐37–treated group n=8). C, Representative M‐mode echocardiography images of the left ventricle on day 28 post‐ MI . Left ventricular end‐diastolic dimension (LVEDD), left ventricular end‐systolic dimension (LVESD), ejection fraction (EF%), and fractional shortening (FS%) on day 7 (D) and day 28 (E) post‐ MI (Sham n=6, PBS ‐treated group n=6, and IL ‐37‐treated group n=8). * P <0.05 and ** P <0.01.
Human Il 37 Elisa Kit, supplied by Hangzhou Eastbiopharm Co, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human il-37 elisa kit/product/Hangzhou Eastbiopharm Co
Average 90 stars, based on 1 article reviews
human il-37 elisa kit - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Beijing Solarbio Science elisa kit for human il-37
Interleukin <t>(IL)–37</t> reduces myocardial infarct size and improves left ventricular function following myocardial infarction (MI). A, Survival analysis in PBS ‐treated and IL ‐37–treated mice after MI . B, Infarct size determined by 2, 3, 5‐triphenyltetrazolium chloride staining of sections on day 1 post‐ MI ( PBS ‐treated group n=6 and IL ‐37–treated group n=8). C, Representative M‐mode echocardiography images of the left ventricle on day 28 post‐ MI . Left ventricular end‐diastolic dimension (LVEDD), left ventricular end‐systolic dimension (LVESD), ejection fraction (EF%), and fractional shortening (FS%) on day 7 (D) and day 28 (E) post‐ MI (Sham n=6, PBS ‐treated group n=6, and IL ‐37‐treated group n=8). * P <0.05 and ** P <0.01.
Elisa Kit For Human Il 37, supplied by Beijing Solarbio Science, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/elisa kit for human il-37/product/Beijing Solarbio Science
Average 90 stars, based on 1 article reviews
elisa kit for human il-37 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
ELK Biotechnology human glucagon-like peptide 1 (glp-1, 7-37) elisa kit elk5218
Interleukin <t>(IL)–37</t> reduces myocardial infarct size and improves left ventricular function following myocardial infarction (MI). A, Survival analysis in PBS ‐treated and IL ‐37–treated mice after MI . B, Infarct size determined by 2, 3, 5‐triphenyltetrazolium chloride staining of sections on day 1 post‐ MI ( PBS ‐treated group n=6 and IL ‐37–treated group n=8). C, Representative M‐mode echocardiography images of the left ventricle on day 28 post‐ MI . Left ventricular end‐diastolic dimension (LVEDD), left ventricular end‐systolic dimension (LVESD), ejection fraction (EF%), and fractional shortening (FS%) on day 7 (D) and day 28 (E) post‐ MI (Sham n=6, PBS ‐treated group n=6, and IL ‐37‐treated group n=8). * P <0.05 and ** P <0.01.
Human Glucagon Like Peptide 1 (Glp 1, 7 37) Elisa Kit Elk5218, supplied by ELK Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human glucagon-like peptide 1 (glp-1, 7-37) elisa kit elk5218/product/ELK Biotechnology
Average 90 stars, based on 1 article reviews
human glucagon-like peptide 1 (glp-1, 7-37) elisa kit elk5218 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

94
Guangzhou JET Bio-Filtration human ll-37 (antibacterial protein ll-37) elisa kit
Interleukin <t>(IL)–37</t> reduces myocardial infarct size and improves left ventricular function following myocardial infarction (MI). A, Survival analysis in PBS ‐treated and IL ‐37–treated mice after MI . B, Infarct size determined by 2, 3, 5‐triphenyltetrazolium chloride staining of sections on day 1 post‐ MI ( PBS ‐treated group n=6 and IL ‐37–treated group n=8). C, Representative M‐mode echocardiography images of the left ventricle on day 28 post‐ MI . Left ventricular end‐diastolic dimension (LVEDD), left ventricular end‐systolic dimension (LVESD), ejection fraction (EF%), and fractional shortening (FS%) on day 7 (D) and day 28 (E) post‐ MI (Sham n=6, PBS ‐treated group n=6, and IL ‐37‐treated group n=8). * P <0.05 and ** P <0.01.
Human Ll 37 (Antibacterial Protein Ll 37) Elisa Kit, supplied by Guangzhou JET Bio-Filtration, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human ll-37 (antibacterial protein ll-37) elisa kit/product/Guangzhou JET Bio-Filtration
Average 94 stars, based on 1 article reviews
human ll-37 (antibacterial protein ll-37) elisa kit - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier

Image Search Results


Interleukin (IL)–37 reduces myocardial infarct size and improves left ventricular function following myocardial infarction (MI). A, Survival analysis in PBS ‐treated and IL ‐37–treated mice after MI . B, Infarct size determined by 2, 3, 5‐triphenyltetrazolium chloride staining of sections on day 1 post‐ MI ( PBS ‐treated group n=6 and IL ‐37–treated group n=8). C, Representative M‐mode echocardiography images of the left ventricle on day 28 post‐ MI . Left ventricular end‐diastolic dimension (LVEDD), left ventricular end‐systolic dimension (LVESD), ejection fraction (EF%), and fractional shortening (FS%) on day 7 (D) and day 28 (E) post‐ MI (Sham n=6, PBS ‐treated group n=6, and IL ‐37‐treated group n=8). * P <0.05 and ** P <0.01.

Journal: Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease

Article Title: Interleukin‐37 and Dendritic Cells Treated With Interleukin‐37 Plus Troponin I Ameliorate Cardiac Remodeling After Myocardial Infarction

doi: 10.1161/JAHA.116.004406

Figure Lengend Snippet: Interleukin (IL)–37 reduces myocardial infarct size and improves left ventricular function following myocardial infarction (MI). A, Survival analysis in PBS ‐treated and IL ‐37–treated mice after MI . B, Infarct size determined by 2, 3, 5‐triphenyltetrazolium chloride staining of sections on day 1 post‐ MI ( PBS ‐treated group n=6 and IL ‐37–treated group n=8). C, Representative M‐mode echocardiography images of the left ventricle on day 28 post‐ MI . Left ventricular end‐diastolic dimension (LVEDD), left ventricular end‐systolic dimension (LVESD), ejection fraction (EF%), and fractional shortening (FS%) on day 7 (D) and day 28 (E) post‐ MI (Sham n=6, PBS ‐treated group n=6, and IL ‐37‐treated group n=8). * P <0.05 and ** P <0.01.

Article Snippet: The groups were as follows: (1) the sham group (sham), in which C57BL/6 mice were subjected to sham operation; (2) the recombinant human IL‐37 (Adipogen AG, Liestal, Switzerland) treatment group (IL‐37+MI); and (3) the PBS treatment group (PBS+MI), in which the mice were injected intraperitoneally with 1 μg of recombinant human IL‐37 diluted in 200 μL PBS or with 200 μL PBS only, respectively, 15 minutes prior to MI or 24 hours after MI.

Techniques: Staining

Interleukin (IL)–37 inhibited cardiomyocyte apoptosis in vivo. A, Representative images of terminal deoxynucleotidyl transferase dUTP nick‐end labeling (TUNEL)–stained heart sections from different groups 1 day and 28 days post–myocardial infarction ( MI ). TUNEL (green) and 4, 6‐diamidino‐2‐phenylindole (blue) staining of nuclei in apoptotic cardiomyocytes (red) in the peri‐infarct zone. B, Quantitative analysis of the percentages of TUNEL ‐positive nuclei (n=6). Scale bar: 100 μm. ** P <0.01.

Journal: Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease

Article Title: Interleukin‐37 and Dendritic Cells Treated With Interleukin‐37 Plus Troponin I Ameliorate Cardiac Remodeling After Myocardial Infarction

doi: 10.1161/JAHA.116.004406

Figure Lengend Snippet: Interleukin (IL)–37 inhibited cardiomyocyte apoptosis in vivo. A, Representative images of terminal deoxynucleotidyl transferase dUTP nick‐end labeling (TUNEL)–stained heart sections from different groups 1 day and 28 days post–myocardial infarction ( MI ). TUNEL (green) and 4, 6‐diamidino‐2‐phenylindole (blue) staining of nuclei in apoptotic cardiomyocytes (red) in the peri‐infarct zone. B, Quantitative analysis of the percentages of TUNEL ‐positive nuclei (n=6). Scale bar: 100 μm. ** P <0.01.

Article Snippet: The groups were as follows: (1) the sham group (sham), in which C57BL/6 mice were subjected to sham operation; (2) the recombinant human IL‐37 (Adipogen AG, Liestal, Switzerland) treatment group (IL‐37+MI); and (3) the PBS treatment group (PBS+MI), in which the mice were injected intraperitoneally with 1 μg of recombinant human IL‐37 diluted in 200 μL PBS or with 200 μL PBS only, respectively, 15 minutes prior to MI or 24 hours after MI.

Techniques: In Vivo, TUNEL Assay, Staining

Effects of interleukin (IL)–37 on regulatory T cells (Tregs), T helper (Th)1, and Th17 cells in spleens of C57 BL /6 mice on day 7 after myocardial infarction (MI). A, CD 4 + T‐cell subsets were gated, and representative images of Tregs, Th1, and Th17 cells are shown. B, Results of statistical analysis of average percentages of Tregs, Th1, and Th17 cells. C, Absolute numbers of Tregs, Th1, and Th17 cells were counted in the spleen. n=6 per group. APC indicates activated protein C; FITC, fluorescein isothiocyanate. ** P <0.01 vs sham and ## P <0.01 vs PBS + MI .

Journal: Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease

Article Title: Interleukin‐37 and Dendritic Cells Treated With Interleukin‐37 Plus Troponin I Ameliorate Cardiac Remodeling After Myocardial Infarction

doi: 10.1161/JAHA.116.004406

Figure Lengend Snippet: Effects of interleukin (IL)–37 on regulatory T cells (Tregs), T helper (Th)1, and Th17 cells in spleens of C57 BL /6 mice on day 7 after myocardial infarction (MI). A, CD 4 + T‐cell subsets were gated, and representative images of Tregs, Th1, and Th17 cells are shown. B, Results of statistical analysis of average percentages of Tregs, Th1, and Th17 cells. C, Absolute numbers of Tregs, Th1, and Th17 cells were counted in the spleen. n=6 per group. APC indicates activated protein C; FITC, fluorescein isothiocyanate. ** P <0.01 vs sham and ## P <0.01 vs PBS + MI .

Article Snippet: The groups were as follows: (1) the sham group (sham), in which C57BL/6 mice were subjected to sham operation; (2) the recombinant human IL‐37 (Adipogen AG, Liestal, Switzerland) treatment group (IL‐37+MI); and (3) the PBS treatment group (PBS+MI), in which the mice were injected intraperitoneally with 1 μg of recombinant human IL‐37 diluted in 200 μL PBS or with 200 μL PBS only, respectively, 15 minutes prior to MI or 24 hours after MI.

Techniques:

Interleukin (IL)–37 plus troponin I (TnI)–treated dendritic cells (DCs) display tolerogenic properties. A, Bone marrow–derived DCs (2×10 5 cells/well) were cultured in the absence of stimulus (immature DC s [im DC s]) or in the presence of 1 μg/mL lipopolysaccharide (LPS) ( mature DCs [mDC s]) or 10 ng/mL LPS , 30 ng/mL IL ‐37, and 1 μg/mL TnIk ( tolerogenic DCs [tDC s]). DCs were stained with isotype control antibodies or with specific antibodies against major histocompatibility complex class II (MHC‐II), CD 40, and CD 86 and analyzed by fluorescence‐activated cell sorting. B, Mean fluorescence intensities (MFIs) for MHC ‐ II , CD 40, and CD 86 were quantified. C, Analysis of the mRNA levels of IL ‐10, transforming growth factor‐β (TGF‐β), indolamine 2, 3‐dioxygenase (IDO), interferon‐γ (IFN‐γ), and IL ‐12 in different DC s groups. n=6 per group. ** P <0.01.

Journal: Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease

Article Title: Interleukin‐37 and Dendritic Cells Treated With Interleukin‐37 Plus Troponin I Ameliorate Cardiac Remodeling After Myocardial Infarction

doi: 10.1161/JAHA.116.004406

Figure Lengend Snippet: Interleukin (IL)–37 plus troponin I (TnI)–treated dendritic cells (DCs) display tolerogenic properties. A, Bone marrow–derived DCs (2×10 5 cells/well) were cultured in the absence of stimulus (immature DC s [im DC s]) or in the presence of 1 μg/mL lipopolysaccharide (LPS) ( mature DCs [mDC s]) or 10 ng/mL LPS , 30 ng/mL IL ‐37, and 1 μg/mL TnIk ( tolerogenic DCs [tDC s]). DCs were stained with isotype control antibodies or with specific antibodies against major histocompatibility complex class II (MHC‐II), CD 40, and CD 86 and analyzed by fluorescence‐activated cell sorting. B, Mean fluorescence intensities (MFIs) for MHC ‐ II , CD 40, and CD 86 were quantified. C, Analysis of the mRNA levels of IL ‐10, transforming growth factor‐β (TGF‐β), indolamine 2, 3‐dioxygenase (IDO), interferon‐γ (IFN‐γ), and IL ‐12 in different DC s groups. n=6 per group. ** P <0.01.

Article Snippet: The groups were as follows: (1) the sham group (sham), in which C57BL/6 mice were subjected to sham operation; (2) the recombinant human IL‐37 (Adipogen AG, Liestal, Switzerland) treatment group (IL‐37+MI); and (3) the PBS treatment group (PBS+MI), in which the mice were injected intraperitoneally with 1 μg of recombinant human IL‐37 diluted in 200 μL PBS or with 200 μL PBS only, respectively, 15 minutes prior to MI or 24 hours after MI.

Techniques: Derivative Assay, Cell Culture, Staining, Fluorescence, FACS

Inflammatory cells infiltration and cytokines expression in the infarcted heart after treatment with interleukin ( IL )‐37 or tolerogenic dendritic cells (tDCs) 24 hours post–myocardial infarction (MI). A, Representative images of infiltration of myeloperoxidase (MPO + ) neutrophils, mouse CD 107b (Mac3 + ) macrophages, and CD 3 + T cells in the border area of the infarct hearts. Images for neutrophils and macrophages are from day 3 after MI , and images for T cells are from day 7 post‐ MI . B, Infiltration of neutrophils, macrophages, and T cells were compared between the different groups. C, Analysis of mRNA levels of tumor necrosis factor‐α (TNF‐α) and IL ‐10 on day 7 after MI . Data are depicted as fold changes vs PBS + MI . n=5 per group. Scale bar: 100 μm. ** P <0.01 vs PBS + MI .

Journal: Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease

Article Title: Interleukin‐37 and Dendritic Cells Treated With Interleukin‐37 Plus Troponin I Ameliorate Cardiac Remodeling After Myocardial Infarction

doi: 10.1161/JAHA.116.004406

Figure Lengend Snippet: Inflammatory cells infiltration and cytokines expression in the infarcted heart after treatment with interleukin ( IL )‐37 or tolerogenic dendritic cells (tDCs) 24 hours post–myocardial infarction (MI). A, Representative images of infiltration of myeloperoxidase (MPO + ) neutrophils, mouse CD 107b (Mac3 + ) macrophages, and CD 3 + T cells in the border area of the infarct hearts. Images for neutrophils and macrophages are from day 3 after MI , and images for T cells are from day 7 post‐ MI . B, Infiltration of neutrophils, macrophages, and T cells were compared between the different groups. C, Analysis of mRNA levels of tumor necrosis factor‐α (TNF‐α) and IL ‐10 on day 7 after MI . Data are depicted as fold changes vs PBS + MI . n=5 per group. Scale bar: 100 μm. ** P <0.01 vs PBS + MI .

Article Snippet: The groups were as follows: (1) the sham group (sham), in which C57BL/6 mice were subjected to sham operation; (2) the recombinant human IL‐37 (Adipogen AG, Liestal, Switzerland) treatment group (IL‐37+MI); and (3) the PBS treatment group (PBS+MI), in which the mice were injected intraperitoneally with 1 μg of recombinant human IL‐37 diluted in 200 μL PBS or with 200 μL PBS only, respectively, 15 minutes prior to MI or 24 hours after MI.

Techniques: Expressing